Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia-Reference-Cited by-同舟云学术

Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia

Published:2019-02-04 Issue:1 Volume:14 Page:
ISSN:1750-1172
Container-title:Orphanet Journal of Rare Diseases
language:en
Short-container-title:Orphanet J Rare Dis

Author:

Buscarini Elisabetta^ORCID, ,Botella Luisa Maria,Geisthoff Urban,Kjeldsen Anette D.,Mager Hans Jurgen,Pagella Fabio,Suppressa Patrizia,Zarrabeitia Roberto,Dupuis-Girod Sophie,Shovlin Claire L.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Genetics (clinical),General Medicine

Link

http://link.springer.com/content/pdf/10.1186/s13023-018-0982-4.pdf

Reference73 articles.

1. Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJ, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet. 2000;91:66–7.

2. McDonald J, Wooderchak-Donahue W, VanSant WC, Whitehead K, Stevenson DA, Bayrak-Toydemir P. Hereditary hemorrhagic telangiectasia: genetics and molecular diagnostics in a new era. Front Genet. 2015;6:1.

3. Shovlin CL, Buscarini E, Kjeldsen AD, Mager HJ, Sabba C, Droege F, et al. European reference network for rare vascular diseases (VASCERN) outcome measures for hereditary Haemorrhagic telangiectasia (HHT). Orphanet J Rare Dis. 2018;13:136.

4. Faughnan ME, Palda VA, Garcia-Tsao G, Geisthoff UW, McDonald J, Proctor DD, et al. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet. 2011;48:73–87.

5. European Association for the Study of the Liver. Vascular diseases of the liver. Garcia-Pagàn JC, Buscarini E, Janssen HL, Leebeck FW, Plessier A, Rubbia Brandt L et al. J Hepatol 2016; 64:179–202.

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Role of Thalidomide and Its Analogs in the Treatment of Hereditary Hemorrhagic Telangiectasia: A Systematic Review;Journal of Clinical Medicine;2024-09-12

2. Hereditary hemorrhagic telangiectasia (Osler’s disease): systemic, interdisciplinary, relatively common—and often missed;Deutsches Ärzteblatt international;2024-09-06

3. Targeted treatments for vascular malformations: current state of the art;Journal of Thrombosis and Haemostasis;2024-08

4. The double whammy of ER-retention and dominant-negative effects in numerous autosomal dominant diseases: significance in disease mechanisms and therapy;Journal of Biomedical Science;2024-06-27

5. Hepatic manifestations of hereditary haemorrhagic telangiectasia;Liver International;2024-06-07